MIDAS and HIT‐6 Questionnaires Versus Headache Diaries for Monitoring Treatment Response to Erenumab in Migraine: A REFORM Study

Read full text Summarise with VIRAT
Authors: Janu Thuraiaiyah, Rune Häckert Christensen, Haidar M. Al‐Khazali, Messoud Ashina, Zaza Katsarava, Håkan Ashina
Cited by: 0
References: 30

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND: Headache diaries are the gold standard for assessing preventive migraine treatments but can be burdensome. The Migraine Disability Assessment (MIDAS) and the six-item Headache Impact Test (HIT-6) offer alternatives for monitoring treatment response, though their effectiveness in identifying treatment responders is unclear relative to diary-based measures. This study evaluated how well MIDAS and HIT-6 distinguish responders from non-responders to erenumab, and aimed to determine cut-off scores that best align with a ≥ 50% reduction in monthly migraine days (MMDs). METHODS: This prospective, open-label study enrolled adults with migraine who received 140 mg erenumab for 24 weeks. Treatment response was a ≥ 50% reduction in MMDs based on diary data. MIDAS and HIT-6 were completed at baseline, Week 12, and Week 24. Discriminative ability and optimal cut-offs were determined using receiver operating characteristic curve analysis. RESULTS: Among 582 participants, 300 individuals (52%) achieved a ≥ 50% reduction in MMDs. MIDAS and HIT-6 demonstrated fair discriminative ability in identifying treatment responders, with area under the curve values ranging from 0.71 to 0.77. The optimal MIDAS cut-offs were either a 16-point absolute reduction (78% sensitivity, 60% specificity) or a 49% relative reduction (82% sensitivity, 64% specificity). For HIT-6, optimal thresholds included an 8-point reduction (53% sensitivity, 84% specificity) or a 12% relative reduction (54% sensitivity, 84% specificity). Sensitivity analyses using alternative response definitions confirmed the primary findings. CONCLUSIONS: Although MIDAS and HIT-6 contribute meaningful information on treatment-related disability reduction, these retrospective tools lack sufficient precision to replace prospective headache diaries in assessing response to erenumab. TRIAL REGISTRATION: NCT04603976.

Fields of Study & Subjects

Migraine and Headache Studies Temporomandibular Joint Disorders Intracranial Aneurysms: Treatment and Complications

Publication details

Journal / source
European Journal of Neurology
Volume
33
Issue
4
Pages
e70542–e70542
Publication date
27 March 2026
Language
EN